negatives of retatrutide Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide (“reta”) is an experimental

What has changed is the size of the audience that needs it and the urgency of the timeline

Regulatory Environment Notice

At 40 weeks, mean body weight changes were 7.5 kg with 10 mg and 8.8 kg with 15 mg doses, compared to 1.6 kg with placebo

Recently, BCGs Center for Customer Insight (CCI) surveyed more than 1,500 GLP-1 users in nine markets

For downloadable product images for use in media articles, please access the multimedia release here: *US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events, Cardiovascular Drugs and Therapy, August 15, 2023 **Measuring GLP-1 Efficacy in the Real World, Dandelion Research, 2024 ***These statements have not been evaluated by the Food and Drug Administration

Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP